<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03151057</url>
  </required_header>
  <id_info>
    <org_study_id>J1633</org_study_id>
    <secondary_id>IRB00157704</secondary_id>
    <nct_id>NCT03151057</nct_id>
  </id_info>
  <brief_title>Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies</brief_title>
  <official_title>Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies: A Phase 1 Double Blinded Randomized Placebo Toxicity Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the safety of idelalisib as post-transplantation maintenance in&#xD;
      patients with B cell hematologic malignancies undergoing a allogeneic hematopoietic stem cell&#xD;
      transplant (HSCT). Safety will be evaluated through the assessment of cytopenias, effect on&#xD;
      donor chimerism, effect on the incidence and severity of acute graft versus host disease, and&#xD;
      gastro-intestinal tolerance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, to improve overall survival, the focus of the BMT program at JHH the introduction&#xD;
      of anti-neoplastic therapy post transplantation: where the allo BMT serves as a platform to&#xD;
      allowing a new intolerant immune system to interact with the post allo BMT intervention.&#xD;
&#xD;
      The importance of post BMT therapy has been made evident with tyrosine kinase inhibition&#xD;
      (TKI) in Philadelphia chromosome positive acute lymphocytic leukemia (ALL) and chronic&#xD;
      myeloid leukemia(CML), where patients who had disease progression while on TKI therapy&#xD;
      pre-allo BMT enjoy marked improvement in overall survival when TKI is part of a maintenance&#xD;
      program; the use of DNA hypomethylation agents after allo BMT for relapsed myeloid&#xD;
      malignances; or the use of rituximab after allo BMT in follicular lymphoma.&#xD;
&#xD;
      Idelalisib, an orally-administered, selective inhibitor of Phosphoinositide 3 kinase (PI3K),&#xD;
      is extremely effective in inducing partial responses to complete responses in many B-cell&#xD;
      derived malignancies and should be studied in the post alloHSCT setting. Johns Hopkins&#xD;
      Hospital has one of the world's largest experiences with alloHSCT. This study proposes a&#xD;
      double blinded randomized phase I placebo trial where all patients who have undergone&#xD;
      alloHSCT for a B-cell derived hematologic malignancy be offered either idelalisib 100mg or&#xD;
      placebo twice daily for 180 days starting approximately 90 days after their HSCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Idelalisib 100mg or placebo twice daily, starting day +90 (+-/ 10 days) after transplant until day +270.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Participant, investigator</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-limiting toxicities will be defined as Idelalisib interruption for &gt;14 days, or other &gt;3 adverse events as defined by CTCAE IV not captured in the protocol for dose de-escalation.</measure>
    <time_frame>Day 90 - Day 270 post transplant</time_frame>
    <description>The evaluation of the safety of Idelalisib as post-transplantation maintenance in patients with B cell hematologic malignancies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event free survival at one year.</measure>
    <time_frame>Beginning Day 90 post transplant until Day 360</time_frame>
    <description>Impact of Idelalisib on aGVHD, relapse, and non-relapse mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify potential predictive biomarker candidates based on exploratory gene expression analysis of immune biomarkers in bone marrow aspirates and whole or targeted exome sequencing of lymphoma cells</measure>
    <time_frame>Beginning Day 90 post transplant until Day 270</time_frame>
    <description>Search for Biomarkers which could better identify which patients would respond to treatment with Idelalisib in the post-transplant setting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>B Cells-Tumors</condition>
  <condition>B Cell Chronic Lymphocytic Leukemia</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)</condition>
  <arm_group>
    <arm_group_label>Idelalisib 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idelalisib is an orally-administered, selective inhibitor of Phosphoinositide 3 kinase (PI3K)-delta which has been shown to be extremely effective in inducing partial to complete responses in many B-cell derived malignancies.&#xD;
intervention: 100mg Idelalisib twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to be taken twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib 100 MG</intervention_name>
    <description>100mg BID beginning on day 90 (+/- 10days) and continuing until day 270 post transplant.</description>
    <arm_group_label>Idelalisib 100mg</arm_group_label>
    <other_name>Zydelig</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo oral tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          1. &gt;18 years of age&#xD;
&#xD;
          2. Has undergone allo HSCT to treat a B-cell derived hematologic malignancy: accepted&#xD;
             alloHSCT regimens include: myeloablative or reduced intensity conditioning from any&#xD;
             donor (matched, partially mismatched or cord) and any source (peripheral blood, bone&#xD;
             marrow, or cord).&#xD;
&#xD;
          3. T bili ≤ 1.5 mg/dL except for patients with Gilbert's syndrome or hemolysis&#xD;
&#xD;
          4. AST, ALT and alk phos all &lt; 2.5X ULN&#xD;
&#xD;
          5. Karnofsky performance score ≥ 40&#xD;
&#xD;
          6. ECOG ≤3&#xD;
&#xD;
          7. For women of childbearing potential, a negative serum or urine pregnancy test with&#xD;
             sensitivity less than 50 mIU/m within 72 hours before the start of study medication.&#xD;
&#xD;
          8. Use of two forms of contraception with less than a 5% failure rate or abstinence by&#xD;
             all transplanted patients for a minimum of 1 month after the last dose of Idelalisib.&#xD;
             For the first 60 days post-transplant, transplant recipients should be encouraged to&#xD;
             use non-hormonal contraceptives due to the potential adverse effect of hormones on&#xD;
             bone marrow engraftment.&#xD;
&#xD;
          9. Ability to receive oral medication.&#xD;
&#xD;
         10. Ability to understand and provide informed consent.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          1. ECOG &gt;3 (Karnofsky &lt;40%)&#xD;
&#xD;
          2. ALT, AST &gt;2.5 ULN or total bilirubin &gt;1.5 ULN (not attributable to Gilbert's)&#xD;
&#xD;
          3. Women who are pregnant or breastfeeding.&#xD;
&#xD;
          4. Exclude if patient has cirrhosis or is currently being actively treated for hepatitis&#xD;
             C.&#xD;
&#xD;
          5. History of positive HIV-1 or HIV-2 serologies or nucleic acid test.&#xD;
&#xD;
          6. Active hepatitis B infection as documented by positive Hepatitis B PCR assay&#xD;
&#xD;
          7. Use of investigational drug, other than the study medications specified by the&#xD;
             protocol, within 30 days of transplantation.&#xD;
&#xD;
          8. Receipt of a live vaccine within 30 days of receipt of study therapy.&#xD;
&#xD;
          9. ≥ Grade II aGVHD&#xD;
&#xD;
         10. The presence of any medical condition that the Investigator deems incompatible with&#xD;
             participation in the trial&#xD;
&#xD;
         11. Subjects who are required to use a medication classified as a strong CYP3A inducer of&#xD;
             inhibitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Gladstone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idelalisib</keyword>
  <keyword>Zydelig</keyword>
  <keyword>allo transplant</keyword>
  <keyword>PI3K inhibitor</keyword>
  <keyword>post transplant maintenance therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idelalisib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 3, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT03151057/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

